SCHEMBL538845

SCHEMBL538845

C=CCNC1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL818299 0.95
SCHEMBL1485739 0.92 DPP7 (0.52)
SCHEMBL7533868 0.92 DPP7 (0.52)
SCHEMBL14473427 0.92 DPP7 (0.52)
SCHEMBL7536595 0.92 DPP7 (0.52)
SCHEMBL479254 0.92 DPP7 (0.52)
SCHEMBL17291811 0.90 DPP7 (0.36)
Hydrochloric Acid SCHEMBL2864272 0.90 DPP7 (0.50)
Ammonia Solution, Strong SCHEMBL6390287 0.90 DPP7 (0.50)
SCHEMBL7735833 0.89 KMT2A (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002531400-A 2002-09-24 JP claimed
EP-1133288-A1 THE USE OF ARYL-SUBSTITUTED CYCLOBUTYLALKYLAMINES FOR TREATING URINARY INCONTINENCE KNOLL AKTIENGESELLSCHAFT (DE) 2001-09-19 EP claimed
US-6127424-A N-METHYL-1-(1-(4-CHLOROPHENYL)CYCLOBUTYL)-3-METHYLBUTYLAMINE OR A PHARMACEUTICALLY SUITABLE SALT AS AN EXAMPLE; BIOAVAILABILITY; SIDE EFFECT REDUCTION KNOLL AKTIENGESESLLSCHAFT (DE) 2000-10-03 US claimed
WO-2000032182-A1 THE USE OF ARYL-SUBSTITUTED CYCLOBUTYLALKYLAMINES FOR TREATING URINARY INCONTINENCE KNOLL AKTIENGESELLSCHAFT (DE) 2000-06-08 WO claimed
US-6046242-A ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE BASF AKTIENGESELLSCHAFT (DE) 2000-04-04 US claimed
CN-116670140-A Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-29 CN disclosed
WO-2023147104-A1 METHODS FOR THE PREPARATION OF ETHYL 3-BROMO-1-(3-CHLOROPYRIDIN-2-YL)-4,5-DIHYDRO-1 H-PYRAZOLE-5- CARBOXYLATE FMC CORPORATION (US) 2023-08-03 WO disclosed
US-20230086433-A1 METHODS FOR THE PREPARATION OF ETHYL 3-BROMO-1-(3-CHLOROPYRIDIN-2-YL)-1H-PYRAZOLE-5-CARBOXYLATE FMC IP TECHNOLOGY GMBH (CH) 2023-03-23 US disclosed
EP-4017847-A1 PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID DERIVATIVES OF 3-BROMO-4,5-DIHYDRO-1H-PYRAZOLES FMC CORPORATION (US) 2022-06-29 EP disclosed
EP-3919479-A1 COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF Bionna (Beijing) Medical Technology Co., Ltd. (CN) 2021-12-08 EP disclosed
WO-2021142344-A1 METHODS FOR THE PREPARATION OF ETHYL 3-BROMO-1-(3-CHLOROPYRIDIN-2-YL)-1H-PYRAZOLE-5-CARBOXYLATE FMC CORPORATION (US) 2021-07-15 WO disclosed
WO-2021034904-A1 PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID DERIVATIVES OF 3-BROMO-4,5-DIHYDRO-1H-PYRAZOLES FMC CORPORATION (US) 2021-02-25 WO disclosed
US-6046242-A ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE BASF AKTIENGESELLSCHAFT (DE) 2000-04-04 US disclosed
US-6046242-A ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE BASF AKTIENGESELLSCHAFT (DE) 2000-04-04 US disclosed
US-6046242-A ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE BASF AKTIENGESELLSCHAFT (DE) 2000-04-04 US disclosed
EP-0828484-A1 USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY Knoll AG (DE) 1998-03-18 EP disclosed
EP-0828484-A1 USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY Knoll AG (DE) 1998-03-18 EP disclosed
WO-1996038134-A1 USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY KNOLL AG (DE) 1996-12-05 WO disclosed
WO-1996038134-A1 USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY KNOLL AG (DE) 1996-12-05 WO disclosed
US-3965220-A AMINE CATALYST MONSANTO COMPANY (US) 1976-06-22 US disclosed